Related Experiment Video
Updated: Aug 21, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Effectiveness of propagermanium treatment in multiple myeloma patients
Yutaka Tsutsumi1, Junji Tanaka, Hiroe Kanamori
1Department of Internal Medicine, Hakodate Municipal Hospital, Hakodate, Japan. rtsutsu@nyc.odn.ne.jp
Abstract:
Interferon (IFN) is one of several drugs effective in treating multiple myeloma (MM), and propagermanium is an IFN inducer. We report on 10 MM patients who were treated with propagermanium at doses from 10 to 40 mg. Two patients achieved complete remission (CR), two patients achieved partial remission (PR), and the condition of four patients was stable (stable disease, SD). After discontinuation of propagermanium, the status of MM progressed in two patients who were in SD and in two patients who had achieved PR. The administration of propagermanium was restarted in one patient resulting in a decrease in her paraprotein.
